^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRAF mutation

    i
    Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
    Entrez ID:
    673
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    1d
    Micro-GIST with BRAF mutation arising in a Leiomyoma: a rare case report and literature review. (PubMed, Z Gastroenterol)
    The patient remained in a satisfactory condition post-surgery. This case report describes the first documented micro-GIST with a BRAF mutation arising in a leiomyoma, highlighting the importance of molecular detection in the differential diagnosis of GISTs.
    Review • Journal
    |
    BRAF (B-raf proto-oncogene) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    BRAF mutation • KIT mutation • PDGFRA mutation
    1d
    Ultrarapid BRAF mutation detection on supernatant cell-free DNA obtained by FNA: An accurate and expedient method for BRAF assessment in aggressive thyroid carcinomas. (PubMed, Cancer Cytopathol)
    The Idylla BRAF assay delivers ultrarapid results that are both reliable and accurate with high success rates, particularly on ScfDNA samples. ScfDNA samples also have the fastest TAT because no histologic processing or pre-extraction are required for testing.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF mutation • BRAF V600
    1d
    Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=47, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | N=33 --> 47
    Trial completion • Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF mutation • BRAF V600 • RAS wild-type • BRAF positive
    |
    Erbitux (cetuximab) • Zelboraf (vemurafenib) • irinotecan
    2d
    Cohort Study on the Prognostic Impact of Sequential Local Ablation Therapy, Chemotherapy, and Targeted Therapy Versus Combination of Immunotherapy and Targeted Therapy in the Third-Line Treatment of Metastatic Colorectal Cancer (ChiCTR2600121514)
    P=N/A, N=300, Recruiting, China-Japan Friendship Hospital; Beijing University of Chinese Medicine
    New trial
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF mutation
    2d
    Becotatug Vedotin Combined with Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer (ChiCTR2600121010)
    P2, N=31, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
    |
    MSI-H/dMMR • BRAF mutation • RAS wild-type
    |
    Erbitux (cetuximab) • Meiyouheng (becotatug vedotin)
    2d
    Clinicopathological Characteristics and Prognostic Analysis of Thyroid Cancer Combined with Breast Cancer: A Retrospective Study Based on a Single-Center Real-World Cohort and the SEER Database (ChiCTR2600120907)
    P=N/A, N=8600, Recruiting, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    New trial • Real-world evidence
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • HER-2 mutation
    2d
    Clinicopathological and Genetic Mutations of Papillary Thyroid Carcinoma (ChiCTR2600119910)
    P=N/A, N=45, Completed, Sulaimani university; Sulaimani university
    New trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    2d
    Development and Validation of a Predictive Model for Chemoradiotherapy Response and Prognosis in Mid-Low Locally Advanced Rectal Cancer Based on Transcriptomic Profiling and Clinical Characteristics (ChiCTR2600119769)
    P=N/A, N=934, Taizhou Cancer Hospital; Taizhou Cancer Hospital
    New trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    2d
    A Multicenter, Randomized, Controlled, Open-label, Phase II Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Treatment of Advanced Melanoma (ChiCTR2600118298)
    P2, N=92, Beijing Cancer Hospital (Peking University Cancer Hospital); Beijing Cancer Hospital (Peking University Cancer Hospital)
    New P2 trial
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF mutation • NRAS mutation • BRAF V600 • BRAF positive
    |
    cisplatin • carboplatin • paclitaxel • temozolomide • dacarbazine • LM103
    3d
    Diagnostic Utility of PRAME and H3K27me3 in Distinguishing Malignant Melanoma From Proliferative Nodules on Congenital Melanocytic Nevi. (PubMed, J Cutan Pathol)
    Combined use of PRAME and H3K27me3 can be utilized to discriminate MM from PN arising in LCMN/GCMN if validated on larger cohorts.
    Journal
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • GNAQ (G Protein Subunit Alpha Q) • TERT (Telomerase Reverse Transcriptase) • GNA11 (G Protein Subunit Alpha 11) • PRAME (Preferentially Expressed Antigen In Melanoma)
    |
    BRAF mutation • NRAS mutation
    3d
    Phenotypic plasticity in plasma cell myeloma: a CD138-negative case with a rare BRAF G469R mutation. (PubMed, J Pathol Transl Med)
    The patient exhibited poor response to bortezomib, lenalidomide, and dexamethasone therapy, necessitating a switch to carfilzomib-based treatment. This case underscores the diagnostic challenges of CD138-negative myeloma and highlights the importance of integrating morphology, immunophenotyping, and molecular profiling to inform accurate diagnosis and guide therapeutic strategies.
    Journal
    |
    BRAF (B-raf proto-oncogene) • CD20 (Membrane Spanning 4-Domains A1) • SDC1 (Syndecan 1) • VIM (Vimentin) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    BRAF mutation • CD20 positive
    |
    lenalidomide • bortezomib • carfilzomib • dexamethasone
    3d
    Clinical and Radiometabolic Correlatives of ddPCR Liquid Biopsy for BRAF V600 Mutated Melanoma. (PubMed, Int J Cancer)
    The PET-CT calculated total metabolic tumor volume correlated with the quantitative ctDNA result with a Pearson r factor of 0.49. In conclusion, ctDNA ddPCR BRAF testing is easily obtained and might be especially beneficial for patients diagnosed with a clinically aggressive disease, based on elevated LDH, higher PET-CT metabolic tumor volume, and younger age.
    Journal • Liquid biopsy
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600 • LDH elevation